D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Proceedings ArticleDOI
Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC
Mark A. Socinski,Sarah M. Paul,Cindy Yun,Sylvia Hu,Vincent Shen,Vamsidar Velcheti,Tony Mok,David R. Gandara,Young Kwang Chae,Erica B. Schleifman,David Fabrizio,David S. Shames,See Phan,Edward S. Kim +13 more
TL;DR: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients with low circulating tumor DNA in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC shows consistency with previous findings regarding low levels of ctDNA, pts with MSAF.
Journal ArticleDOI
Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer.
Umberto Malapelle,Pasquale Pisapia,Alfredo Addeo,Oscar Arrieta,Beatriz Bellosillo,Andrés F. Cardona,Massimo Cristofanilli,Diego de Miguel-Pérez,Diego de Miguel-Pérez,Valeria Denninghoff,Ignacio Duran,Eloisa Jantus-Lewintre,Pier Vitale Nuzzo,Kenneth J. O'Byrne,Patrick Pauwels,Edward M. Pickering,Luis E. Raez,Alessandro Russo,María José Serrano,David R. Gandara,Giancarlo Troncone,Christian Rolfo +21 more
TL;DR: In this paper, a review summarizes the available evidence on pre-analytical issues and different clinical applications of liquid biopsies in NSCLC patients, with a focus on the optimization and standardization of all phases of liquid-biopsy samples management in order to determine a significant improvement in either sensitivity or specificity.
Journal ArticleDOI
ARQ 197 in patients with previously-treated malignant mesothelioma (MM): A phase II trial from the University of Chicago Phase II Consortium.
Steven Brad Maron,Theodore Karrison,Rajani Kanteti,Krishna Rao,David R. Gandara,Marianna Koczywas,Ravi Salgia,Hedy L. Kindler +7 more
TL;DR: This data indicates that suppression of HGF in response to the MET receptor tyrosine kinase antagonist acts as a “spatially aggregating force” to IGF-1 in MM cells.
Journal Article
Neoadjuvant therapy for non-small cell lung cancer.
TL;DR: Clinical trials evaluating neoadjuvant or preoperative therapy for locally advanced non-small cell lung cancer (NSCLC) have demonstrated the feasibility, tolerability and activity of this approach, and docetaxel, one of the most active agents in first- and second-line chemotherapy of NSCLC, and a potent radiosensitizer, is investigated.
Journal ArticleDOI
Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer
David T. Cooke,David R. Gandara,Neal Goodwin,Royce F. Calhoun,Primo N. Lara,Philip C. Mack,Elizabeth A. David +6 more
TL;DR: It is suggested that thoracic surgical biopsy can be safely performed in appropriately selected patients with stage IV non-small cell lung cancer and direct personalized therapy and enrollment into relevant clinical trials.